VRDN

Viridian Therapeutics, Inc. Common Stock
Data: 2026-06-03
$16.35
Price
3.02%
Change
$34.29
52W High
$13.18
52W Low

Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).

Quick Stats
Jun 03, 2026

53.0

AI Score

HOLD

0.57

Volume Ratio

Aug 06, 2026

Next Earnings

14

+ve Days (30d)

16

-ve Days (30d)

VRDN Stock Summary

Last updated Jun 03, 2026

VRDN is currently trading at $16.35, positioned below its 200-day moving average of $24.28, suggesting bearish momentum. The stock has a 52-week range of $13.18 to $34.29.

Technical Analysis: The 50-day moving average stands at $16.9, which is above the current price, indicating bearish near-term pressure. The RSI (Relative Strength Index) reads 45.588, suggesting the stock is neutral with balanced momentum.

Money Flow Indicators: The Chaikin Money Flow (20-day) is -0.256, which is negative, suggesting distribution or selling pressure. Our AI-powered investment score rates VRDN at 53.0/100 with a HOLD recommendation.

VRDN (Viridian Therapeutics, Inc. Common Stock) Indicators

Last updated Jun 03, 2026

Indicator Value
RSI(14) 45.588
CMF (20) -0.256
ROC (10) 1.691
ADX (14) 22.604
Indicator Value
MACD (12,26,9) -0.106
AROONOSC (14) 28.571
WILLAMS %R (14) -76.863
MFI (14) 41.638
VRDN Technical Chart
  • Candlesticks: Green = price up, Red = price down. Body shows open/close, wicks show high/low.
  • SMAs: Moving averages help identify trends. Price above SMA = bullish, below = bearish.
  • Options OI: Shows max open interest strikes. High OI = significant price levels.
  • Volume Profile: Shows price levels with most trading activity. POC = Point of Control (highest volume).
  • Earnings: Vertical lines mark earnings dates. Watch for volatility around these dates.
  • Gamma Walls: Key support/resistance from options gamma exposure. Orange = resistance above, Purple = support below.
  • Fibonacci Retracement: Auto-calculated support/resistance levels based on recent high/low. Key levels: 23.6%, 38.2%, 50%, 61.8%, 78.6%.
  • Unusual Activity: Highlights days with abnormal volume (2x+ average) or large price moves (5%+). Red marker = unusual activity detected.
Technical Indicators

Select indicators above to analyze technical patterns

Indicators will appear below the price chart with perfectly aligned dates

Volume Profile Analysis

Horizontal histogram showing volume distribution at each price level with buying/selling pressure

VRDN Price vs Max Options Open Interest
VRDN Max Change In Options Open Interest

VRDN Options - Sort by Max open Interest (near term)

3rd June 2026 (Data is delayed in normal mkt. hours)

Type Expiration Strike OI Change in
OI
Volume Ask PC Delta Vega Volatility % change Track

VRDN Daily Out of Money Options - Sort by Max open Interest (near term)

3rd June 2026 (Data is delayed in normal mkt. hours)

Type Expiration Strike OI Change in
OI
Volume Ask PC Delta Vega Volatility % change Track

VRDN Daily In the Money Options - Sort by Max open Interest (near term)

3rd June 2026 (Data is delayed in normal mkt. hours)

Type Expiration Strike OI Change in
OI
Volume Ask PC Delta Vega Volatility % change Track

VRDN Most Active Options by Volume(near term)

3rd June 2026 (Data is delayed in normal mkt. hours)

Type Expiration Strike Volume OI Change in
OI
Ask PC Delta Vega Volatility % change Track

Viridian Therapeutics, Inc. Common Stock is not trading above both 50 Day and 200 Day SMA which is considered Bearish.

VRDN Moving Averages Analysis

VRDN (Viridian Therapeutics, Inc. Common Stock) Simple Moving Averages

Moving Averages are last updated Jun 03, 2026

Days MA
10 17.11
20 16.98
30 16.07
50 16.9
100 23.55
200 24.28

VRDN Fundamental Analysis

P/E (Forward) 1.0072
P/E (Trailing) --
Market Cap ($) 1.8 billion
Earnings/Share ($) -3.35
Net Proft Margin (%) 0
Dividend/Share ($) --
EPS Estimate Current Year ($) -3.8148
EPS Estimate Next Year ($) -2.5107
WallStreet Target Price ($) 33.9375
Most Recent Quarter